Research analysts at Bank of America Corporation initiated coverage on shares of NewLink Genetics Corporation (NASDAQ:NLNK) in a note issued to investors on Friday, The Fly reports. The brokerage set a “buy” rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on NLNK. Robert W. Baird upgraded shares of NewLink Genetics Corporation from a “neutral” rating to an “outperform” rating and upped their target price for the company from $8.00 to $22.00 in a report on Friday, September 8th. Zacks Investment Research cut shares of NewLink Genetics Corporation from a “hold” rating to a “sell” rating in a report on Wednesday, July 12th. Jefferies Group LLC restated a “hold” rating and issued a $7.00 target price on shares of NewLink Genetics Corporation in a report on Friday, July 14th. Cantor Fitzgerald set a $26.00 target price on shares of NewLink Genetics Corporation and gave the company a “buy” rating in a report on Friday, July 28th. Finally, ValuEngine cut shares of NewLink Genetics Corporation from a “sell” rating to a “strong sell” rating in a report on Tuesday, September 26th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $26.60.

NewLink Genetics Corporation (NASDAQ:NLNK) last announced its quarterly earnings data on Friday, July 28th. The biotechnology company reported ($0.57) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.78) by $0.21. NewLink Genetics Corporation had a negative net margin of 161.94% and a negative return on equity of 55.03%. The company had revenue of $10.37 million for the quarter, compared to the consensus estimate of $2.65 million.

TRADEMARK VIOLATION WARNING: “NewLink Genetics Corporation (NLNK) Now Covered by Analysts at Bank of America Corporation” was first reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another website, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/13/newlink-genetics-corporation-nlnk-now-covered-by-analysts-at-bank-of-america-corporation.html.

In related news, major shareholder Stine Seed Farm, Inc. bought 780,487 shares of the stock in a transaction dated Friday, October 6th. The stock was acquired at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the acquisition, the insider now owns 7,857,732 shares in the company, valued at approximately $80,541,753. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 13.70% of the company’s stock.

Several institutional investors have recently modified their holdings of NLNK. Tyers Asset Management LLC acquired a new position in shares of NewLink Genetics Corporation in the 4th quarter valued at $114,000. State of Wisconsin Investment Board acquired a new stake in NewLink Genetics Corporation during the 2nd quarter worth $125,000. Trexquant Investment LP boosted its stake in NewLink Genetics Corporation by 39.1% during the 2nd quarter. Trexquant Investment LP now owns 18,132 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 5,097 shares during the period. Advisor Group Inc. boosted its stake in NewLink Genetics Corporation by 3.4% during the 2nd quarter. Advisor Group Inc. now owns 18,082 shares of the biotechnology company’s stock worth $133,000 after purchasing an additional 600 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in NewLink Genetics Corporation by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,069 shares of the biotechnology company’s stock worth $140,000 after purchasing an additional 556 shares during the period. Institutional investors and hedge funds own 54.77% of the company’s stock.

About NewLink Genetics Corporation

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

The Fly

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.